Is The Andromeda Strain a Hit or Flop? Official Box Office Record & Profit Analysis

Detailed Financial Report

The Andromeda Strain, released in 1971, entered the cinematic marketplace as a Science Fiction / Thriller film. The production path for this project involved significant capital, with a reported budget of approximately $6.5M. In the modern film economy, recovering such an investment requires a multifaceted theatrical strategy spanning domestic and international territories.

Collection Trajectory

The box office journey for The Andromeda Strain has culminated in a worldwide gross of approximately $12.4M. This figure represents the total theatrical footprint, reflecting a Return on Investment (ROI) of 90%. Although not a breakout sensation, the collection figures demonstrate a reliable performance that contributes to the studio's annual slate.

Profitability & Verdict

Analyzing the multiplier effect and market sentiment, The Andromeda Strain navigated the competitive landscape with an audience reception score of 7/10. When weighing the production costs against the global returns, The Andromeda Strain is effectively categorized as a Average. A solid success that demonstrates effective resource allocation and content-market fit.

Comparables

In the context of other Science Fiction releases, the performance of The Andromeda Strain will likely influence how studios approach similar projects in the future. Whether through its innovative visual style or its narrative choices, the film's financial footprint remains a key piece of the 1971 box office narrative.